What recent development has BioNexus announced regarding the VitaGuard™ platform in Southeast Asia, and what role did its visit to China play?

BioNexus Gene Lab Corp. announced progress in commercializing its VitaGuard™ molecular residual disease (MRD) platform in Southeast Asia following a working visit to Tongshu Gene's facilities in China; the visit involved technical planning and meetings with Chinese hospitals where VitaGuard is already in commercial use.

What is BioNexus's strategic objective for VitaGuard™ in Southeast Asia, and how does its investment in Fidelion Diagnostics relate to the platform's global expansion?

BioNexus aims to lead the rollout of VitaGuard™ in Southeast Asia, while its investment in Fidelion Diagnostics supports broader international market opportunities for the platform.

BioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Visit

Jul 28, 2026

BioNexus Gene Lab Corp announced progress commercializing its VitaGuard™ molecular residual disease platform in Southeast Asia after technical planning visits to Chinese facilities. The company aims to lead the regional rollout while leveraging investments in Fidelion Diagnostics for broader international opportunities.

GlobeNewswire

BioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working Visit

Yahoo Finance

2026-02-23

BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman

2026-03-12

BioNexus Gene Lab Corp. Appoints Dr. Muthu Meyyappan as CCO of Fidelion Diagnostics to Lead VitaGuard™ MRD Commercialization

2026-04-04

BioNexus Gene Lab Corp Stock Drops 3% on Poor Ratings

2026-04-14

BioNexus Gene Lab 10-K: Revenue $7.42M, EPS $(1.61)